Director/PDMR Shareholding

RNS Number : 2459G

Hikma Pharmaceuticals Plc

09 May 2011

 



Hikma Pharmaceuticals PLC - Share Transactions

LONDON, 9 May 2011: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) announces that the following Persons Discharging Managerial Responsibility ("PDMR") have exercised awards which vested on 29 April 2011 under the 2005 Long Term Incentive Plan ("LTIP") and which in two cases the holder was required to exercise as part of the vesting process. The exercise price under the LTIP is £nil. The persons concerned elected to retain all the shares exercised, subject to, in one case, a disposal to meet a tax liability arising.

In accordance with DTR 3.1.2R and s.793 of the Companies Act 2006, Hikma announces that the following transactions took place in London over the Company's Ordinary Shares of 10p each as detailed below.

PDMR	Type of Transaction	Exercised	Date	Price	Shares Disposed	Outstanding Holding
Mazen Darwazah	Exercise of LTIP 2007 & 2008	104,000 (0.06% ISC)	9 May 2011	£7.92	Nil	799,225 (0.41%)
Bassam Kanaan	Exercise of LTIP 2008	54,000 (0.03% ISC)	9 May 2011	£7.92	Nil	379,568 (0.19% ISC)
Michael Raya	Exercise of LTIP 2008	27,000 (0.01% ISC)	9 May 2011	£7.92	14,800 (0.01% ISC)	12,200 (0.01% ISC)
Majda Labadi	Exercise of LTIP 2008	54,000 (0.03% ISC)	9 May 2011	£7.92	Nil	108,445 (0.06%)

- ENDS -

Enquiries:

Hikma Pharmaceuticals PLC         

Henry Knowles                                                [phone]

Company Secretary

Susan Ringdal                                                 [phone]

Investor Relations Director

About Hikma

Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed pharmaceutical products.  Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics".  Hikma's operations are based principally in the Middle East and North Africa ("MENA") region, where it is a market leader and sells across 17 countries, the United States and Europe.  In 2010, the Group achieved revenues of $731 million (2009 $637 million) and profit attributable to shareholders was $99 million (2009 $78 million).  For news and other information, please visit www.hikma.com.

 

END

 

 

RDSBLGDUUSGBGBC